Updates in Treatment of NSCLC with Classical EGFR Mutations
A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
Read More
Challenges Associated with Molecular Testing in NSCLC
A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
Read More
Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?
A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
Read More
Liquid Biopsies in the NSCLC Molecular Testing Algorithm
Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
Read More
Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice
Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
Read More
Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer
August 16th 2019Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.
Read More